中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (6): 2417-2418.doi: 10.4103/NRR.NRR-D-25-00140

• 观点:退行性病与再生 • 上一篇    下一篇

将焦点转移到临床前阶段:蓝斑Tau病理作为阿尔茨海默病的驱动因素和治疗靶点

  

  • 出版日期:2026-06-15 发布日期:2025-09-18

Shifting focus to preclinical stages: Locus coeruleus tau pathology as a driver and therapeutic target in Alzheimer’s disease

Qi Yuan* , Tamunotonye Omoluabi, Brandon F. Hannam   

  1. Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada
  • Online:2026-06-15 Published:2025-09-18
  • Contact: Qi Yuan, PhD, qyuan@mun.ca.
  • Supported by:
    This work was supported by the Canadian Institutes of Health Research Project grant (PJT169197) to QY. BFH was supported by a CGS-M fellowship from the Canadian Institutes of Health Research.

摘要: https://orcid.org/0000-0002-9837-8495 (Qi Yuan)

Abstract: Alzheimer’s disease (AD) remains an incurable neurodegenerative disorder with devastating societal and personal impacts. Despite decades of intensive research, therapeutic efforts targeting the clinical stages of AD have largely failed to halt or reverse disease progression. This has prompted a critical shift in focus toward the earlier, preclinical stages of AD, where interventions may hold greater promise for altering the disease trajectory. Theoretical frameworks of preclinical AD, such as those proposed by Sperling et al. (2011), describe a continuum spanning over a decade or more, characterized by three progressive stages: asymptomatic amyloidosis, the onset of neurodegeneration, and subtle cognitive impairments. While this model emphasizes amyloid-β as the initiating pathology, mounting evidence challenges this amyloid-centric paradigm, positioning early tau pathology as a primary driver of early neurodegenerative changes.